The CEO of Danish pharmaceutical giant Novo Nordisk, known for its blockbuster weight-loss drug Ozempic, will step down ...

Wegovy-maker Novo Nordisk said on Friday its CEO Lars Fruergaard Jorgensen will step down over concerns the company is losing ...

Jørgensen has agreed to stay on while the search for a successor is carried out, and the chair of the Novo Nordisk Foundation ...

As Novo Nordisk's share price drops, CEO Lars Fruergaard Jorgensen steps down. The company aims to maintain its lead in the competitive weight-loss drug market.

"Considering the recent market challenges, the share price decline, and the wish from the Novo Nordisk Foundation, the Novo Nordisk Board and Lars Fruergaard Jørgensen have jointly concluded that ...

Novo’s shares have plunged since hitting a record-high in June last year as competition, particularly from Eli Lilly, makes inroads into its market share and as its pipeline of new drugs has ...

Novo Nordisk announced on Friday morning that its CEO Lars Fruergaard Jørgensen is stepping down after leading the company for eight years. In a release announcing the decision, the Danish pharma ...

Days earlier, Novo Nordisk cut its sales and profit forecast for first time since the launch of Wegovy four years ago.

Danish drugmaker Novo Nordisk, known for its blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, said Friday ...

Novo Nordisk said Friday it will replace its CEO, citing a sharp tumble for Novo shares amid growing competition.

The company behind the weight loss sensation that transformed bodies and bank accounts across America just showed its own CEO ...

In study after study, injected GLP-1 weight loss medications appear to work better on average for women than they do for men.